Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347003 · ClinicalTrials.gov registry record · Phase 3

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
446
Enrollment target
20
Study locations

NCT06347003: Active Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.

NCT06347003 is a Phase 3 study of Severe Hypertriglyceridemia that is active but no longer recruiting, run by Arrowhead Pharmaceuticals. The registered enrollment target is 446 participants, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347003, a Phase 3 study of Severe Hypertriglyceridemia, is active but no longer recruiting, sponsored by Arrowhead Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
446 participants
Enrollment target
20
Study locations

Study Summary

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Conditions Studied

Severe Hypertriglyceridemia

Interventions

  • DRUG Placebo
  • DRUG Plozasiran Injection

Study Locations (20)

Florida

  • Research Center 7 - Hialeah
  • Research Center 8 - Lake City
  • Research Center 9 - Miami Lakes
  • Research Center 10 - Mt. Dora
  • Research Center 11 - Orlando
  • Research Center 12 - Pensacola
  • Research Center 13 - Tamarac
  • Research Center 14 - Tampa

California

  • Research Center 1 - Garden Grove
  • Research Center 2 - Lake Forest
  • Research Center 3 - Montclair
  • Research Center 4 - Panorama City
  • Research Center 5 - Redding

Georgia

  • Research Center 15 - Macon
  • Research Center 16 - Savannah

Colorado

  • Research Center 6 - Colorado Springs

Illinois

  • Research Center 17 - Park Ridge

Louisiana

  • Research Center 18 - Eunice

Maryland

  • Research Center 19 - Baltimore

Michigan

  • Research Center 20 - Flint

Trial Details

FieldValue
Enrollment Target 446 participants
Start Date 2024-07-22
Est. Completion 2026-09
Phase Phase 3
Arrowhead Pharmaceuticals

15 total trials

What the registry record for NCT06347003 still lists

NCT06347003 is an interventional study that assigns participants to a tested intervention. The registered 446 participants enrollment target is mid-sized for trials with a published cap, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher).

The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06347003 names 20 study sites across 8 states, led by Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06347003 about?

NCT06347003 is a clinical study titled "Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia". This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and...

What is the current status of trial NCT06347003?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2024-07-22. Estimated completion is 2026-09.

What conditions does trial NCT06347003 study?

This clinical trial studies the following conditions: Severe Hypertriglyceridemia.

What interventions are being tested in trial NCT06347003?

The interventions under investigation include: Placebo (DRUG), Plozasiran Injection (DRUG).

Who is sponsoring clinical trial NCT06347003?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347003 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06347003's enrollment target sits among peer trials

446 3rd of 8 higher than 5 of 8 other Severe Hypertriglyceridemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Severe Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04065399 · 447 participants · Phase 1

    A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

  • NCT03504800 · 445 participants

    OCT in Diagnosis of Irregular Corneas

  • NCT04751435 · 445 participants · NA

    Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06347003, the US trial registry maintained by the National Library of Medicine. NCT06347003 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.